Palmitoyl Tripeptide-5 (Peptide)

Palmitoyl Tripeptide-5 is a synthetic lipopeptide composed of a palmitoyl fatty acid chain linked to the tripeptide sequence Lys-Val-Lys, designed to mimic the collagen-stimulating domain of thrombospondin-1. It activates TGF-β (transforming growth factor-beta) signaling pathways to upregulate collagen types I, II, and IV synthesis in dermal fibroblasts.

Origin & History

Palmitoyl Tripeptide-5 is a synthetic peptide with the sequence Pal-Lys-Val-Lys-OH, chemically classified as a palmitoylated tripeptide that mimics a fragment of human Thrombospondin I (TSP-1). It is produced via liquid-phase synthesis methods using convergent coupling of protected amino acids with palmitoyl chloride, avoiding solid-phase drawbacks like high costs and pollution. This compound has no natural origin and is fully laboratory-synthesized.

Historical & Cultural Context

Palmitoyl Tripeptide-5 has no historical or traditional use in any medicine systems. It is a modern synthetic peptide developed for cosmetic applications with no pre-commercial or cultural context.

Health Benefits

• Stimulates collagen synthesis (types I, II, IV) through TGF-β activation (in-vitro evidence only)
• Promotes fibronectin production and extracellular matrix repair (in-vitro evidence only)
• May reduce matrix metalloproteases (MMPs) expression (theoretical mechanism, no clinical evidence)
• Potentially reduces pro-inflammatory cytokines and vasodilation (theoretical mechanism, no clinical evidence)
• Previously used in cosmetic mix for type I rosacea redness reduction (anecdotal evidence, study details unavailable)

How It Works

Palmitoyl Tripeptide-5 mimics the sequence of thrombospondin-1, a natural activator of latent TGF-β, binding to and activating TGF-β receptors on dermal fibroblasts to upregulate transcription of collagen types I, II, and IV. This cascade also promotes fibronectin secretion and extracellular matrix (ECM) remodeling by downregulating matrix metalloproteinases (MMPs), particularly MMP-1 and MMP-3, which are enzymes responsible for collagen degradation. The palmitoyl lipid chain facilitates percutaneous absorption by increasing the peptide's affinity for the stratum corneum lipid bilayer.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Palmitoyl Tripeptide-5 according to available sources. Only in-vitro studies demonstrate its ability to activate TGF-β and stimulate collagen synthesis. No PubMed PMIDs are available for human studies.

Clinical Summary

The majority of evidence supporting Palmitoyl Tripeptide-5 derives from in-vitro fibroblast cell culture studies demonstrating increased collagen and fibronectin gene expression, with limited translation to robust human clinical trials. One manufacturer-sponsored split-face study reported measurable reductions in wrinkle depth after 12 weeks of twice-daily topical application at concentrations around 4 ppm, though full methodology and sample sizes were not independently peer-reviewed. No large-scale, placebo-controlled randomized clinical trials (RCTs) with statistically significant, independently replicated outcomes have been published in indexed journals as of 2024. Evidence strength is currently rated low-to-moderate, and claims of efficacy should be interpreted cautiously pending independent clinical validation.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "carbohydrates": "Not applicable", "fats": "Not applicable", "fiber": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"Palmitoyl Tripeptide-5": "Concentration not typically quantified in nutritional terms; used in cosmetic formulations for skin benefits.", "Bioavailability": "Topical application; bioavailability depends on formulation and skin penetration enhancers."}}

Preparation & Dosage

No clinically studied dosage ranges have been established for Palmitoyl Tripeptide-5 as no human trials are documented. Commercial formulations contain approximately 900-1300 ppm (about 1g peptide per 1kg solution). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Retinol, Hyaluronic Acid, Copper Peptides, Matrixyl

Safety & Interactions

Palmitoyl Tripeptide-5 has a well-established topical safety profile and is generally considered non-irritating, non-sensitizing, and non-comedogenic at concentrations used in cosmetic formulations (typically 0.001%–0.01% by weight). No significant systemic absorption has been documented at standard topical doses, and no known drug interactions have been reported for dermal application. It is not classified as a drug by the FDA, so no formal contraindications exist; however, individuals with known hypersensitivity to palmitoyl peptides should perform patch testing prior to use. Data on safety during pregnancy and lactation are insufficient, and caution is advised as a precautionary measure.